Clinical relevance of immune monitoring in solid organ transplantation

International Reviews of Immunology

Volumn 28, Issue 3-4, 2009, Pages 155-184

  Daniel, Volker ^a   Opelz, Gerhard ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Clinical relevance; Immune monitoring; Immunosuppression; Patient; Solid organ transplantation; Tolerance induction

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTIMETABOLITE; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CD3 ANTIBODY; CD30 ANTIGEN; CYCLOSPORIN; CYTOKINE; GAMMA INTERFERON; HLA ANTIBODY; IDIOTYPIC ANTIBODY; IMMUNOSUPPRESSIVE AGENT; INDOLEAMINE 2,3 DIOXYGENASE; MESSENGER RNA; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; TRANSCRIPTION FACTOR NFAT;

ACUTE GRAFT REJECTION; ALLOIMMUNITY; AUTOIMMUNITY; BLOOD SAMPLING; CANCER RISK; CHEMOTAXIS; CHRONIC GRAFT REJECTION; CIRCADIAN RHYTHM; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROL GROUP; DENDRITIC CELL; DIABETES MELLITUS; DNA POLYMORPHISM; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG MONITORING; DRUG POTENTIATION; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSPOT ASSAY; GENE EXPRESSION REGULATION; GRAFT FAILURE; GRAFT INFECTION; GRAFT REJECTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNE DEFICIENCY; IMMUNOGENICITY; IMMUNOREGULATION; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INFECTION RISK; KIDNEY GRAFT REJECTION; LYMPHOCYTE ACTIVATION; MICROARRAY ANALYSIS; MICROCHIMERISM; MONOCYTE; NEOPLASM; NEPHROTOXICITY; ORGAN TRANSPLANTATION; PATIENT MONITORING; PERIPHERAL LYMPHOCYTE; POSTOPERATIVE PERIOD; PRE T LYMPHOCYTE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RECIPIENT; REGULATORY T LYMPHOCYTE; REVIEW; SIDE EFFECT; SUPPRESSOR CELL; SURGICAL RISK; T LYMPHOCYTE SUBPOPULATION; TRANSPLANTATION TOLERANCE; URINALYSIS;

ANIMALS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE AGENTS; MONITORING, IMMUNOLOGIC; ORGAN TRANSPLANTATION;

EID: 70350678968     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.1080/08830180902929404     Document Type: Review

References (83)

1. J.E. Murray, Surgeon scientist.World J Surg 24: 757-758, 2000.
2. CTS Collaborative Transplant Study. Accessed 5 May, 2009 at: http://ctstransplant. org.
3. M. Banasik and M. Klinger, Chronic allograft nephropathy-immunologic and nonimmunologic factors. Ann Transplant 11: 7-10, 2006.
4. CTS Collaborative Transplant Study, unpublished data
5. S. Bremer, R. Mandla,N.T. Vethe, I. Rasmussen, H. Rootwelt, P.D. Line, K. Midtvedt, and S.Bergan, Expression of IMPDH1 and IMPDH2 after transplantation and initiation of immunosuppression. Transplantation 85: 55-61, 2008.
6. A. Koch, V. Daniel, T.J. Dengler, P.A. Schnabel, S. Hagl, and F.U. Sack, Effectivity of a T-cell-adapted induction therapy with anti-thymocyte globulin (Sangstat). J Heart Lung Transplant 24: 708-713, 2005.
7. M.D. Wavamunno and J.R. Chapman, Individualization of immunosuppression: Concepts and rationale. Curr Opin Organ Transplant 13: 604-608, 2008.
8. L. Quteineh, C. Verstuyft, V. Furlan, A. Durrbach, A. Letierce, S. Ferlicot, A.M. Taburet, B. Charpentier, and L. Becquemont, Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients. Basic Clin Pharmacol Toxicol 103: 546-552, 2008.
9. J. Ashton-Chess, M. Giral, S. Brouard, and J.P. Soulillou, Spontaneous operational tolerance after immunosuppressive drug withdrawal in clinical renal allotransplantation. Transplantation 84: 1215-1219, 2007.
10. G.V. Mazariegos, R. Sindhi, A.W. Thomson, and A.Marcos, Clinical tolerance following liver transplantation: long term results and future prospects. Transpl Immunol 17: 114-119, 2007.
11. S. Beaudreuil,D. Samuel,N. Rouas-Freiss, and A.Durrbach, New aspect of immunosuppressive treatment in liver transplantation. How could you induce tolerance in liver transplantation? Transpl Immunol 17: 98-107, 2007.
12. G. Wiëers, J. Gras, C. Bourdeaux, D.Q. Truong, D. Latinne, and R. Reding, Monitoring tolerance after human liver transplantation. Transpl Immunol 17: 83-93, 2007.
13. K.A. Newell and C.P. Larsen, Tolerance assays: Measuring the unknown. Transplantation 81: 1503-1509, 2006.
14. J. Lerut and A. Sanchez-Fueyo, An appraisal of tolerance in liver transplantation. Am J Transplant 6: 1774-1780, 2006.
15. M.J. Wilhelm, J. Pratschke, F. Beato, M. Taal, M. Kusaka, W.W. Hancock, and N.L. Tilney, Activation of the heart by donor brain death accelerates acute rejection after transplantation. Circulation 102: 2426-2433, 2000.
16. D. Mikhalski, K.M. Wissing, L. Ghisdal, N. Broeders, M. Touly, A.D. Hoang, P. Loi, F. Mboti, V. Donckier, P. Vereerstraeten, and D. Abramowicz, Cold ischemia is a major determinant of acute rejection and renal graft survival in the modern era of immunosuppression. Transplantation 85(7 Suppl): S3-9, 2008.
17. B.Y. Choy, T.M. Chan, and K.N. Lai, Recurrent glomerulonephritis after kidney transplantation. Am J Transplant 6: 2535-2542, 2006.
18. T.K.Hendrikx, E.A. vanGurp, W.M. Mol, W. Schoordijk, V.D. Sewgobind, J.N. Ijzermans, W. Weimar, and C.C. Baan, End-stage renal failure and regulatory activities of CD4+CD25bright+FoxP3+ T-cells. Nephrol Dial Transplant 2009 Feb 4. [Epub ahead of print]
19. C.M. Alvarez, G. Opelz, M.C. Giraldo, S. Pelzl, F. Renner, R. Weimer, J. Schmidt, M. Arbeĺaez, L.F. García, and C. Süsal, Evaluation of T-cell receptor repertoires in patients with long-term renal allograft survival. Am J Transplant 5: 746-756, 2005.
20. F. Bettens, J.M. Tiercy, N. Campanile, E. Giostra, P. Majno, L. Rubbia, E. Roosnek, G. Mentha, and J. Villard, Microchimerism after liver transplantation: absence of rejection without abrogation of anti-donor cytotoxic T-lymphocyte-mediated alloreactivity. Liver Transpl 11: 290-297, 2005.
21. G.V. Mazariegos, A.F. Zahorchak, J. Reyes, L. Ostrowski, B. Flynn, A. Zeevi, and A.W. Thomson, Dendritic cell subset ratio in peripheral blood correlates with successful withdrawal of immunosuppression in liver transplant patients. Am J Transplant 3: 689-696, 2003.
22. R. Cortesini and N. Suciu-Foca, The concept of "partial" clinical tolerance. Transpl Immunol 13: 101-104, 2004.
23. W.J. Burlingham, M.H. Pan, B. Mason, S. Ceman, and H.W. Sollinger, Induction of antiidiotypic antibodies to donor HLA-A2 following blood transfusions in a highly sensitized HLA-A2+ recipient. Transplantation 45: 1066-1071, 1988.
24. J. Pratschke, S.G. Tullius, and P. Neuhaus, Brain death associated ischemia/ reperfusion injury. Ann Transplant 9: 78-80, 2004.
25. O. Milĺan, M. Brunet, J.M. Campistol, A. Faura, I. Rojo, E. Vidal, O. Jiḿenez, J. Vives, F. Oppenheimer, and J. Martorell, Pharmacodynamic approach to immunosuppressive therapies using calcineurin inhibitors and mycophenolate mofetil. Clin Chem 49: 1891-1899, 2003.
26. D.C. Brennan, K. Flavin, J.A. Lowell, T.K. Howard, S. Shenoy, S. Burgess, S. Dolan, J.M. Kano, M. Mahon, M.A. Schnitzler, R. Woodward, W. Irish, and G.G. Singer, A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 67: 1011-1018, 1999. (Pubitemid 29200852)
27. S. Suzuki, S. Toyabe, T. Moroda, T. Tada, A. Tsukahara, T. Iiai, M. Minagawa, S. Maruyama, K. Hatakeyama, K. Endoh, and T. Abo, Circadian rhythm of leucocytes and lymphocytes subsets and its possible correlation with the function of the autonomic nervous system. Clin Exp Immunol 110: 500508, 1997.
28. J.H. Gerrits, P. Athanassopoulos, L.M. Vaessen, M. Klepper, W. Weimar, and N.M. van Besouw, Peripheral blood manipulation significantly affects the result of dendritic cell monitoring. Transpl Immunol 17: 169-177, 2007.
29. C. Sommerer, T. Giese, S. Meuer, and M. Zeier, Pharmacodynamic monitoring of calcineurin inhibitor therapy: Is there a clinical benefit? Nephrol Dial Transplant 24: 21-27, 2009.
30. K. Mahalati, P. Belitsky, I. Sketris, K.West, and R. Panek, Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation 68: 55-62, 1999.
31. R.G. Morris, G.R. Russ, M.J. Cervelli, R. Juneja, S.P. McDonald, and T.H. Mathew, Comparison of trough, 2-hour, and limited AUC blood sampling for monitoring cyclosporin (Neoral) at day 7 post-renal transplantation and incidence of rejection in the first month. Ther Drug Monit 24: 479-486, 2002.
32. E. Nemati, B. Einollahi, S. Taheri, M. Moghani-Lankarani, E. Kalantar, N. Simforoosh, M. Nafar, and A.R. Saadat, Cyclosporine trough (C0) and 2-hour postdose (C2) levels: which one is a predictor of graft loss? Transplant Proc 39: 1223-1224, 2007.
33. G. Einecke, M. Schütz, I. Mai, L. Fritsche, M. Giessing, P. Glander, H.H. Neumayer, and K. Budde, Limitations of C2 monitoring in renal transplant recipients. Nephrol Dial Transplant 20: 1463-1470, 2005.
34. T. Giese, M. Zeier, P. Schemmer, W. Uhl, M. Schoels, T. Dengler, M. Buechler, and S. Meuer, Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: a novel perspective toward individually optimized drug doses of cyclosporine A. Transplantation 77: 339-344, 2004.
35. C. Sommerer, T. Giese, J. Schmidt, S. Meuer, and M. Zeier, Cyclosporine A tapering monitored by NFAT-regulated gene expression: A new concept of individual immunosuppression. Transplantation 85: 15-21, 2008.
36. C. Sommerer, M. Konstandin, T. Dengler, J. Schmidt, S. Meuer, M. Zeier, and T. Giese, Pharmacodynamic monitoring of cyclosporine a in renal allograft recipients shows a quantitative relationship between immunosuppression and the occurrence of recurrent infections and malignancies. Transplantation 82: 1280-1285, 2006.
37. M.H. Konstandin, C. Sommerer, A. Doesch, M. Zeier, S.C. Meuer, H.A. Katus, T.J. Dengler, and T. Giese, Pharmacodynamic cyclosporine A-monitoring: Relation of gene expression in lymphocytes to cyclosporine blood levels in cardiac allograft recipients. Transpl Int 20: 1036-1043, 2007.
38. C. Sommerer, W. Hartschuh, A. Enk, S. Meuer, M. Zeier, and T. Giese, Pharmacodynamic immune monitoring of NFAT-regulated genes predicts skin cancer in elderly long-term renal transplant recipients. Clin Transplant 22: 549-554, 2008.
39. J. Gras, G. Wiëers, J.L. Vaerman, D.Q. Truong, E. Sokal, J.B. Otte, B. D́eĺepaut, A. Cornet, J. de Ville de Goyet, D. Latinne, and R. Reding, Early immunological monitoring after pediatric liver transplantation: cytokine immune deviation and graft acceptance in 40 recipients. Liver Transpl 13: 426-433, 2007.
40. C.D. Kim, H.M. Ryu, J.Y. Choi, H.J. Choi, H.J. Choi, J.H. Cho, S.H. Park, D.I. Won, and Y.L. Kim, Association of G-137C IL-18 promoter polymorphism with acute allograft rejection in renal transplant recipients. Transplantation 86: 1610-1614, 2008.
41. D.M. Girnita, M.M. Brooks, S.A. Webber, G.J. Burckart, R. Ferrell, G. Zdanowicz, S. DeCroo, L. Smith, R. Chinnock, C. Canter, L. Addonizio, D. Bernstein, J.K. Kirklin, S. Ranganathan, D. Naftel, A.L. Girnita, and A. Zeevi, Genetic polymorphisms impact the risk of acute rejection in pediatric heart transplantation: a multi-institutional study. Transplantation 85: 1632-1639, 2008.
42. R. Singh, P. Kesarwani, D.K. Ahirwar, R. Kapoor, and R.D. Mittal, Interleukin 8 -251T>A and Interferon gamma +874A>T polymorphism: Potential predictors of allograft outcome in renal transplant recipients from north India. Transpl Immunol 2009 Feb 2. [Epub ahead of print]
43. J. Grinýo, Y. Vanrenterghem, B. Nashan, F. Vincenti, H. Ekberg, K. Lindpaintner, M. Rashford, C. Nasmyth-Miller, A. Voulgari, O. Spleiss, M. Truman, and L. Essioux, Association of four DNA polymorphisms with acute rejection after kidney transplantation. Transpl Int 21: 879-891, 2008.
44. J. Mytilineos, G. Laux, and G. Opelz, Relevance of IL10, TGFbeta1, TNFalpha, and IL4Ralpha gene polymorphisms in kidney transplantation: a collaborative transplant study report. Am J Transplant 4: 1684-1690, 2004.
45. J. Bayliss, J.A. Maguire, M. Bailey, A. Leet, D. Kaye, M. Richardson, P.J. Bergin, J. Dowling, N.M. Thomson, and A.N. Stein, Increased vascular endothelial growth factor mRNA in endomyocardial biopsies from allografts demonstrating severe acute rejection: A longitudinal study. Transpl Immunol 18: 264-274, 2008.
46. S. Brouard, E. Mansfield, C. Braud, L. Li, M. Giral, S.C. Hsieh, D. Baeten, M. Zhang, J. Ashton-Chess, C. Braudeau, F. Hsieh, A. Dupont, A. Pallier, A. Moreau, S. Louis, C. Ruiz, O. Salvatierra, J.P. Soulillou, and M. Sarwal, Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci U S A 104: 15448-15453, 2007.
47. M. Martínez-Llordella, J.J. Lozano, I. Puig-Pey, G. Orlando, G. Tisone, J. Lerut, C. Benítez, J.A. Pons, P. Parrilla, P. Ramírez,M. Bruguera, A. Rimola, and A. Śanchez- Fueyo, Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest 118: 2845-2857, 2008.
48. J.J. Augustine, E.D. Poggio, P.S. Heeger, and D.E. Hricik, Preferential benefit of antibody induction therapy in kidney recipients with high pretransplant frequencies of donor-reactive interferon-gamma enzyme-linked immunosorbent spots. Transplantation 86: 529-534, 2008.
49. D.E. van den Boogaardt, P.P. van Miert, Y.J. de Vaal, J.W. de Fijter, F.H. Claas, and D.L. Roelen, The ratio of interferon-gamma and interleukin-10 producing donorspecific cells as an in vitro monitoring tool for renal transplant patients. Transplantation 82: 844-848, 2006.
50. S. Pelzl, G. Opelz, M. Wiesel, P. Schnülle, C. Schönemann, B. Döhler, and C. Süsal, Soluble CD30 as a predictor of kidney graft outcome. Transplantation 73: 3-6, 2002.
51. C. Süsal, S. Pelzl, B. Döhler, and G. Opelz, Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30. J Am Soc Nephrol 13: 1650-1656, 2002.
52. S. Pelzl, G. Opelz, V. Daniel, M. Wiesel, and C. Süsal, Evaluation of posttransplantation soluble CD30 for diagnosis of acute renal allograft rejection. Transplantation 75: 421-423, 2003.
53. R. Weimer, C. Süsal, S. Yildiz, A. Staak, S. Pelzl, F. Renner, H. Dietrich, V. Daniel, S. Kamali-Ernst, W. Ernst, W. Padberg, and G.Opelz, Post-transplant sCD30 and neopterin as predictors of chronic allograft nephropathy: Impact of different immunosuppressive regimens. Am J Transplant 6: 1865-1874, 2006.
54. M. Israeli, T. Klein, B. Sredni, Y. Avitzur, E. Mor, N. Bar-Nathen, R. Steinberg, G. Dinari, and R. Shapiro, ImmuKnow: A new parameter in immune monitoring of pediatric liver transplantation recipients. Liver Transpl 14: 893-898, 2008.
55. R.J. Kowalski, D.R. Post, R.B. Mannon, A. Sebastian, H.I. Wright, G. Sigle, J. Burdick, K.A. Elmagd, A. Zeevi, M. Lopez-Cepero, J.A. Daller, H.A. Gritsch, E.F. Reed, J. Jonsson, D. Hawkins, and J.A. Britz, Assessing relative risks of infection and rejection: A meta-analysis using an immune function assay. Transplantation 82: 663-668, 2006.
56. R. Cabrera, M. Ararat, C. Soldevila-Pico, L. Dixon, J.J. Pan, R. Firpi, V. Machicao, C. Levy, D. Nelson, and G. Morelli, Using an immune functional assay to differentiate acute cellular rejection from recurrent hepatitis C in liver transplant patients. Liver Transpl 15: 216-222, 2009.
57. S.M. Bhorade, K. Janata, W.T. Vigneswaran, C.G. Alex, and E.R. Garrity, Cylex ImmuKnow assay levels are lower in lung transplant recipients with infection. J Heart Lung Transplant 27: 990-994, 2008.
58. A. Gautam, S.A. Fischer, A.F. Yango, R.Y. Gohh, P.E. Morrissey, and A.P. Monaco, Cell mediated immunity (CMI) and post transplant viral infections-role of a functional immune assay to titrate immunosuppression. Int Immunopharmacol 6: 2023-2026, 2006.
59. D. Tokita, G.V. Mazariegos, A.F. Zahorchak, N. Chien, M. Abe, G. Raimondi, and A.W. Thomson, High PD-L1/CD86 ratio on plasmacytoid dendritic cells correlates with elevated T-regulatory cells in liver transplant tolerance. Transplantation 85: 369-377, 2008.
60. V. Daniel, C. Naujokat, M. Sadeghi, M. Wiesel, O. Hergesell, and G. Opelz, Association of circulating interleukin (IL)-12- and IL-10-producing dendritic cells with time posttransplant, dose of immunosuppression, and plasma cytokines in renaltransplant recipients. Transplantation 79: 1498-1506, 2005.
61. H. Hackstein, F.C. Renner, A. Bohnert, A. Nockher, T. Frommer, G. Bein, and R. Weimer, Dendritic cell deficiency in the blood of kidney transplant patients on longterm immunosuppression: Results of a prospective matched-cohort study. Am J Transplant 5: 2945-2953, 2005.
62. G. Brandacher, F. Cakar, C. Winkler, S. Schneeberger, P. Obrist, C. Bösmüller, G. Werner-Felmayer, E.R. Werner, H. Bonatti, R. Margreiter, and D. Fuchs, Noninvasive monitoring of kidney allograft rejection through IDO metabolism evaluation. Kidney Int 71: 60-67, 2007.
63. B. Dubínski, M. Boratýnska, W. Kopéc, P. Szyber, D. Patrzalek, and M. Klinger, Activated cells in urine and monocyte chemotactic peptide-1 (MCP-1)-sensitive rejection markers in renal graft recipients. Transpl Immunol 18: 203-207, 2008.
64. R.M. Blanco-Garcia, M.R. Ĺopez-Alvarez, D.A. Pascual-Figal, L. Polo-Garcia, N. Guerra, J.A. Campillo, M. Muro, A.M. Garcia-Alonso, I. Marin-Moreno, M. Valdes, M.R. Alvarez-Ĺopez, and A. Minguela, Expression of HLA molecules on peripheral blood lymphocytes: A useful monitoring parameter in cardiac transplantation. Transplant Proc 39: 2362-2364, 2007.
65. N.Z. Galante, N.O. Câmara, E.G. Kallas, R. Salomão, A. Pacheco-Silva, and J.O. Medina-Pestana, Noninvasive immune monitoring assessed by flow cytometry and real time RT-PCR in urine of renal transplantation recipients. Transpl Immunol 16: 73-80, 2006.
66. P. Saas, C. Courivaud, J. Bamoulid, F. Garnache-Ottou, E. Seilles, and D. Ducloux, Immune monitoring of kidney transplant recipients: Can markers predictive of over-immunosuppression be identified? Ann Pharm Fr 66: 115-121, 2008.
67. V.A. Huurman, R. Hilbrands, G.G. Pinkse, P. Gillard, G. Duinkerken, P. van de Linde, P.M. van der Meer-Prins, M.F. Versteeg-van der Voort Maarschalk, K. Verbeeck, B.Z. Alizadeh, C. Mathieu, F.K. Gorus,D.L. Roelen, F.H. Claas, B.Keymeulen, D.G. Pipeleers, and B.O. Roep, Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation. PLoS ONE 3: e2435, 2008.
68. O. Bestard, J.M. Cruzado, M. Mestre, A. Cald́es, J. Bas, M. Carrera, J. Torras, I. Rama, F. Moreso, D. Seŕon, and J.M. Grinýo, Achieving donor-specific hyporesponsiveness is associated with FOXP3+ regulatory T cell recruitment in human renal allograft infiltrates. J Immunol 179: 4901-4909, 2007.
69. A. Demirkiran, C.C. Baan, A. Kok, H.J. Metselaar, H.W. Tilanus, and L.J. van der Laan, Intrahepatic detection of FOXP3 gene expression after liver transplantation using minimally invasive aspiration biopsy. Transplantation 83: 819-823, 2007.
70. T. Muthukumar, D. Dadhania, R. Ding, C. Snopkowski, R. Naqvi, J.B. Lee, C. Hartono, B. Li, V.K. Sharma, S.V. Seshan, S. Kapur, W.W. Hancock, J.E. Schwartz, and M. Suthanthiran, Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med 353: 2342-2351, 2005.
71. E. Kreijveld, H.J. Koenen, B. van Cranenbroek, E. van Rijssen, I. Joosten, and L.B. Hilbrands, Immunological monitoring of renal transplant recipients to predict acute allograft rejection following the discontinuation of tacrolimus. PLoS ONE 3: e2711, 2008.
72. V. Daniel, C. Naujokat, M. Sadeghi, R. Weimer, F. Renner, S. Yildiz, and G. Opelz, Observational support for an immunoregulatory role of CD3+CD4+CD25+IFNgamma+ blood lymphocytes in kidney transplant recipients with good long-term graft outcome. Transpl Int 21: 646-660, 2008.
73. R. Pretagostini, P. Cinti, Q. Lai, L. Poli, and P.B. Berloco, Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival. Transpl Immunol 20: 3-5, 2008.
74. Y. Zou, P. Stastny, C. Süsal, B. Döhler, and G. Opelz, Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med 357: 1293-1300, 2007.
75. A. Panigrahi, N. Gupta, J.A. Siddiqui, A. Margoob, D. Bhowmik, S. Guleria, and N.K. Mehra, Monitoring of anti-HLA and anti-Major histocompatibility complex class I related chain A antibodies in living related renal donor transplantation. Transplant Proc 39: 759-760, 2007.
76. T. Kobayashi, S. Kohara, Y. Miwa, T. Nagasaka, N. Goto, A. Katayama, K. Uchida, and A. Nakao, Clinical value of HLA antibody monitoring after renal transplantation. Clin Transpl 385-388, 2006.
77. A. Piazza, E. Poggi, G. Ozzella, L. Borrelli, A. Scornajenghi, G. Iaria, G. Tisone, and D. Adorno, Post-transplant donor-specific antibody production and graft outcome in kidney transplantation: Results of sixteen-year monitoring by flow cytometry. Clin Transpl 323-336, 2006.
78. K. Mizutani, P. Terasaki, E. Hamdani, V. Esquenazi, A. Rosen, J. Miller, and M. Ozawa, The importance of anti-HLA-specific antibody strength in monitoring kidney transplant patients. Am J Transplant 7: 1027-1031, 2007.
79. H.S. Pollinger, M.D. Stegall, J.M. Gloor, S.B. Moore, S.R. Degoey, N.A. Ploeger, W.D. Park, H.S. Pollinger, M.D. Stegall, J.M. Gloor, S.B.Moore, S.R. Degoey, N.A. Ploeger, and W.D. Park, Kidney transplantation in patients with antibodies against donor HLA class II. Am J Transplant 7: 857-863, 2007.
80. B.L. Kasiske, H.A. Chakkera, T.A. Louis, and J.Z. Ma, A meta-analysis of immunosuppression withdrawal trials in renal transplantation.JAmSocNephrol 11: 1910- 1917, 2000.
81. P.J. Smak Gregoor, R.G. de Śevaux, G. Ligtenberg, A.J. Hoitsma, R.J. Heńe, W. Weimar, L.B. Hilbrands, and T. van Gelder, Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: A randomized, prospective, multicenter study. J Am Soc Nephrol 13: 1365-1373, 2002.
82. D. Abramowicz, M. Del Carmen Rial, S. Vitko, D. del Castillo, D. Manas, M. Lao, N. Gafner, and P. Wijngaard, Cyclosporine Withdrawal Study Group. Cyclosporine withdrawal from amycophenolate mofetil-containing immunosuppressive regimen: Results of a five-year, prospective, randomized study. J Am Soc Nephrol 16: 2234-2240, 2005.
83. R.Y. Calne, Immunological tolerance-the liver effect. Immunol Rev 174: 280-282, 2000.